// App-Quantinova.ai

POS0225 (2021) : RISK OF MAJOR CARDIOVASCULAR EVENT ACROSS JAK INHIBITOR TREATED PATIENTS: ANALYSIS OF A NATIONAL CLAIM DATABASE

Researchers

Presenter

  • A. Gouverneur

Principal Investigators

  • J. Avouac

  • C. Prati

  • J. L. Cracowski

  • T. Schaeverbeke

  • M. E. Truchetet

Medical Centers

  • Univ. Bordeaux, INSERM, Bordeaux Population Health Research Center, team Pharmaco-epidemiology, UMR 1219, Bordeaux, France.

  • CHU of Bordeaux, Pôle de Santé Publique, Service de Pharmacologie, Bordeaux, France

  • Université de Paris, Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France

  • University Hospital - CHU Minjoz, Rheumatology Unit, Besancon, France

  • Université Grenoble Alpes, INSERM, HP2, Grenoble, France

  • CHU de Bordeaux, Hôpital Pellegrin, Department of Rheumatology, National Reference Center for Systemic Autoimmune Rare Diseases, Bordeaux, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Central Nervous System (CNS)

  • Infectious Diseases (ID)

  • Gastroenterology (GU)

  • Cardiovascular (CVS)

  • Genetic Disorder

Disease

  • Inflammatory bowel disease

  • Transient Ischemic Attack

  • Transient ischemic attack

  • Acute Coronary Syndromes

  • Myocardial infarction

  • Deep vein thrombosis

  • Rheumatoid arthritis

  • Pulmonary embolism

  • Venous thrombosis

  • Inflammatory Arthritis

  • Psoriasis

  • Stroke

Biomarkers

  • Janus kinase

Drug/Treatment

  • Baricitinib

  • Tasocitinib

Outcome

  • N/A

Study Design

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved